ACC 24 - In this video, Dr Gervasio L Lamas (Mount Sinai Medical Center, US) joins us onsite to discuss the findings from the TACT2 study of chelation therapy in post-myocardial infarction patients with diabetes (NCT02733185).

The Trial to Assess Chelation Therapy 2 (TACT2) study is a randomized, double blind factorial clinical trial, aiming to determine if chelation-based strategy increases the time to the first occurrence of all-cause mortality, myocardial infarction, stroke, coronary revascularization or hospitalisation for unstable angina as compared to placebo. This is a 2x2 factorial trial, testing 40-weekly edetate disodium-based chelation infusions and twice daily high-dose oral multivitamins and minerals. 1000 patients with diabetes were enrolled into the study.

Findings showed that EDTA chelation produced a >60% reduction in blood lead levels, however, it did not result in a significant clinical benefit on the primary or secondary endpoints, or on all-cause mortality. 

Interview Questions:

1. What is the importance of this study?
2. What is the mechanism of action behind chelation therapy?
3. What was the study design and patient population?
4. What are your key findings?
5. What should be the impact of these findings on clinical practice?
6. What further study is needed, and what are the next steps?

Recorded onsite at the ACC Conference in Atlanta, 2024.

For more content from ACC.24 head to the Late-breaking Science Video Collection.

Support: This is an independent interview conducted by Radcliffe Cardiology.

Editors: Jordan Rance, Mirjam Boros

Video Specialists: Dan Brent, Tom Green, Mike Knight